Radiopharm Theranostics (ASX:RAD) Interest Coverage: 0 (At Loss) (As of Jun. 2025)


What is Radiopharm Theranostics Interest Coverage?

Radiopharm Theranostics ASX:RAD Interest Coverage is 0 (At Loss) as of Jun. 2025. The stock has 5 warning signs investors should review. Among 377 Biotechnology companies, Radiopharm Theranostics ranks worse than 265251.72% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Radiopharm Theranostics's Operating Income for the six months ended in Jun. 2025 was A$-14.84 Mil. Radiopharm Theranostics's Interest Expense for the six months ended in Jun. 2025 was A$-0.07 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Radiopharm Theranostics's Interest Coverage or its related term are showing as below:


ASX:RAD's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Radiopharm Theranostics  (ASX:RAD) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Radiopharm Theranostics Interest Coverage Related Terms

Radiopharm Theranostics Interest Coverage Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Radiopharm Theranostics Interest Coverage Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Interest Coverage
0.00 0.00 0.00 0.00

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Interest Coverage Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

ASX:RAD vs VRTX, REGN, ALNY: Interest Coverage Comparison

For the Biotechnology subindustry, Radiopharm Theranostics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Interest Coverage falls into.


Radiopharm Theranostics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Radiopharm Theranostics's Interest Coverage for the fiscal year that ended in Jun. 2025 is calculated as

Here, for the fiscal year that ended in Jun. 2025, Radiopharm Theranostics's Interest Expense was A$-0.07 Mil. Its Operating Income was A$-34.64 Mil. And its Long-Term Debt & Capital Lease Obligation was A$0.00 Mil.

Radiopharm Theranostics did not have earnings to cover the interest expense.

Radiopharm Theranostics's Interest Coverage for the quarter that ended in Jun. 2025 is calculated as

Here, for the six months ended in Jun. 2025, Radiopharm Theranostics's Interest Expense was A$-0.07 Mil. Its Operating Income was A$-14.84 Mil. And its Long-Term Debt & Capital Lease Obligation was A$0.00 Mil.

Radiopharm Theranostics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 0 (At Loss) mean?
Radiopharm Theranostics (ASX:RAD) has a Interest Coverage of 0 (At Loss) as of Jun. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Radiopharm Theranostics and its competitors. According to the industry distribution chart, Radiopharm Theranostics ranks #999999 out of 377 companies in the Biotechnology industry.
Is Radiopharm Theranostics' Interest Coverage too high?
Radiopharm Theranostics' current Interest Coverage is 0 (At Loss). Based on the distribution chart, Radiopharm Theranostics ranks #999999 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Radiopharm Theranostics' Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #999999 out of 377 companies for Interest Coverage. This places Radiopharm Theranostics in the lower half of its industry. The industry median Interest Coverage is 106.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Radiopharm Theranostics and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiopharm Theranostics's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Interest Coverage is 0 (At Loss) as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.